introduction: currently, oxidative stress, neuroinflammation and glial activation are accepted as playing a pathophysiological role in complex regional pain syndrome (crps) and consequently antioxidant agents and proinfl ammatory cytokine inhibitors have begun to be assessed in the treatment of this disorder. vimang？ is a new phytodrug prepared from the stem bark of mangifera indica l., registered in cuba with inhibitory effect on nuclear transcription factor kb (nfkb), which induces expression of some mediators and enzymes involved in inflammation, oxidative stress, pain, and synaptic plasticity. objective: to determine the analgesic effects of vimang？ tablets and 1.2% cream as a topical agent in 15 patients with crps, as well as possible improvement in post-treatment functional capacity. material and methods: the patients received a daily dose of 1800 mg of vimang？ tablets for 120 days, 1.2% cream in the affected limb 3 times/day, and sympathetic blocks once a week for 4 months. physiotherapy was introduced after 30 days. the variables evaluated were changes in average daily pain score through a likert scale, the area and rate of dynamic mechanical allodynia, rate of cold allodynia, deep somatic allodynia and frequency of burning spontaneous pain. a modified scale of enneking et al. was applied to evaluate functional capacity. results: the average daily pain score and sensory abnormalities significantly improved from week 2-3. on average, the functional capacity of the affected limb increased from 22.7 % to 78.7%. our results suggest that vimang？ formulations might be useful in crps treatment. however, further studies are required.